Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - metronidazolum - compresse rivestite con film - metronidazolum 250 mg, excipiens pro compresso obducto. - malattie infettive attraverso la digestione anaerobica batteri o protozoi - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - metronidazolum - compresse rivestite con film - metronidazolum 500 mg, excipiens pro compresso obducto. - malattie infettive attraverso la digestione anaerobica batteri o protozoi - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - metronidazolum - ovula - metronidazolum 500 mg, excipiens pro asteraceae ha. - malattie infettive attraverso la digestione anaerobica batteri o protozoi - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

eisai pharma ag - rabeprazolum natricum - compresse rivestite con film - rabeprazolum natricum 10 mg corrisp. rabeprazolum pari a 9.42 mg, mannitolum, magnesio oxidum, hydroxypropylcellulosum sostituto a basso hydroxypropylcellulosum, magnesio stearas, Überzug: ethylcellulosum, magnesio oxidum, hypromellosi phthalas, monoglyceriderorum diacetylates, talco, e 171, e 172 (rosso), cera di carnauba, drucktinte: lacca, e 172 (nero), ethanolum anhydricum, alcol butylicus, per compresso haze corrisp. sodio 0.58 mg. - refluxoesophagitis, ulcustherapie - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

eisai pharma ag - rabeprazolum natricum - compresse rivestite con film - rabeprazolum natricum 20 mg corrisp. rabeprazolum 18.85 mg, mannitolum, magnesio oxidum, hydroxypropylcellulosum sostituto a basso hydroxypropylcellulosum, magnesio stearas, Überzug: ethylcellulosum, magnesio oxidum, hypromellosi phthalas, monoglyceriderorum diacetylates, talco, e 171, e 172 (giallo), cera di carnauba, drucktinte: lacca, e 172 (rosso), cera di carnauba, mono/di/triglycerida, ethanolum anhydricum, alcol butylicus, per compresso haze corrisp. sodio 1.15 mg. - refluxoesophagitis, ulcustherapie - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - rabeprazolum - le compresse gastroresistenti di - rabeprazolum natricum 10 mg corresp. rabeprazolum 9.42 mg, calcii hydroxidum, mannitolum, hydroxypropylcellulosum substitutum humile, natrii stearylis fumaras, Überzug: hypromellosum, talcum, hypromellosi phthalas, dibutylis sebacas, e 171, e 172 (flavum), e 172 (rubrum) pro compresso obducto corresp. natrium 0.71 mg. - refluxoesophagitis, ulcustherapie - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - rabeprazolum - le compresse gastroresistenti di - rabeprazolum natricum 20 mg corresp. rabeprazolum 18.85 mg, calcii hydroxidum, mannitolum, hydroxypropylcellulosum substitutum humile, natrii stearylis fumaras, Überzug: hypromellosum, talcum, hypromellosi phthalas, dibutylis sebacas, e 171, e 172 (flavum) pro compresso obducto corresp. natrium 1.42 mg. - refluxoesophagitis, ulcustherapie - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

sintetica sa - metronidazolum - soluzione per infusione - metronidazolum 500 mg, natrii chloridum, dinatrii phosphas dihydricus, acidum citricum monohydricum, aqua ad iniectabile q.s. ad solutionem pro 100 ml corresp. natrium 318 mg. - infezioni da batteri anaerobici - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

b. braun medical ag - metronidazolum - soluzione per infusione - metronidazolum 500 mg, dinatrii phosphas dodecahydricus, acidum citricum monohydricum, natrii chloridum, aqua ad iniectabile q.s. ad solutionem pro 100 ml corresp. natrium 311 mg. - malattie infettive attraverso anaerobi e protozoi - synthetika

Den Europæiske Union - italiensk - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibatterici per uso sistemico, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..